Methods for nucleic acid mapping and identification of fine-structural-variations in nucleic acids and utilities

• US 7,932,029 B1
• Filed: 01/03/2007
• Issued: 04/26/2011
• Est. Priority Date: 01/04/2006
• Status: Active Grant

• Current Assignee: Si Lok
• Original Assignee: Si Lok
• Inventors: Lok, Si
• Primary Examiner(s): WHISENANT, ETHAN C
• Application Number:
  US11/649,587
• Time in Patent Office: 1,574 Days
• Field of Search: 435/6, 536/23.1, 536/24.3
• US Class Current: 435/6.12
• CPC Class Codes: C12Q 1/6855 Ligating adaptors
• CPC Class Codes: C12Q 1/686 Polymerase chain reaction [PCR]
• CPC Class Codes: C12Q 2521/301 Endonuclease
• CPC Class Codes: C12Q 2521/313 Type II endonucleases, i.e. cutting outside recognition site
• CPC Class Codes: C12Q 2521/501 Ligase
• CPC Class Codes: C12Q 2525/131 incorporating a restriction site
• CPC Class Codes: C12Q 2525/191 incorporating an adaptor

Abstract

The invention disclosed herein describes methods for the mapping and identification of fine-structural variations in nucleic acids.

Claims

1. A method for producing juxtaposed genomic variation tags (GVTs) for determining fine-structural-variations, wherein the juxtaposed GVTs comprise two constituent members of a tag pair (GVT-pair) of a target nucleic acid molecule, the method comprising:

a) providing a target nucleic acid molecule;

b) fragmenting the target nucleic acid molecule to form one or more fragmented target DNA inserts;

c) providing a DNA adaptor, comprising at least one restriction endonuclease recognition sequence, wherein the restriction endonuclease recognition sequence is located at a predetermined sequence position on the DNA adaptor;

d) ligating a DNA adaptor to each end of the fragmented target DNA insert, thereby forming an adaptor-ligated DNA insert, wherein the location of the restriction endonuclease recognition sequence on each DNA adaptor directs cleavage of the fragmented target DNA insert at a predetermined distance from each end of the fragmented target insert;

e) providing a plasmid vector;

f) ligating each end of the adaptor-ligated DNA insert to one end of the plasmid vector, thereby forming a circular plasmid that carries the adaptor-ligated DNA insert;

g) digesting the circular plasmid that carries the adaptor-ligated DNA insert using restriction endonuclease molecules that recognize the restriction endonuclease recognition sequences on the DNA adaptors, thereby generating a linear molecule comprising two genomic variation tags (GVTs), wherein each GVT comprises a terminal sequence of the fragmented target DNA insert, and each GVT is attached to one end of the plasmid vector via a DNA adaptor;

h) recovering said linear molecule comprising two GVTs;

i) recircularizing said linear molecule by intra-molecular ligation, thereby creating a GVT pair comprising two juxtaposed GVTs;

j) corresponding the GVT pair to a reference nucleic acid molecule, wherein each GVT corresponds to a segment of the reference nucleic acid molecule;

k) determining separation distance and orientation between the GVT pair on the target nucleic acid molecule;

l) determining separation distance and orientation between the segments on the reference nucleic acid molecule; and

m) determining whether the target nucleic acid molecule has a fine-structural-variation as compared to the reference nucleic acid molecule by comparing the separation distance and orientation between the GVT pair with the separation distance between the segments on the reference nucleic acid molecule.

4. The method according to claim 1, wherein the two constituent members of the tag pair flank two adjacent and cleavable restriction endonuclease sites for one or more restriction endonucleases in the target nucleic acid molecule.

5. The method of claim 1, wherein the target DNA insert is

genomic DNA, cDNA, viral DNA, microbial DNA, plastid DNA, chemically synthesized DNA, a DNA product of nucleic acid amplification, or DNA transcribed from RNA.

6. The method of claim 1, wherein the target nucleic acid molecule is fragmented, either randomly by the application of mechanical force or by partial digestion with one or more enzymes, to form one or more fragmented target DNA inserts.

7. The method of claim 1 or 2, wherein the target nucleic acid molecule is fragmented by complete digestion using one or more restriction endonucleases alone or in combination to form one or more fragmented target DNA inserts.

8. The method of claim 1 or 2, wherein the fragmented target DNA insert is size fractionated.

9. The method of claim 1 or 2, wherein the fragmented target DNA insert is not size fractionated.

10. The method of claim 1 or 2, wherein a restriction endonuclease used to create the GVT pair is Mme I, NmeA III, CstM I, BceA I, Bpm I, BpuE I, Bsg I, BsmF I, BstV1 I, Eco57 I, Eco57M I, or Gsu I.

11. The method of claim 10, wherein the restriction endonuclease is Mme I.

12. The method of claim 10, wherein the restriction endonuclease is CstM I.

13. The method of claim 10, wherein the restriction endonuclease is NmeA III.

14. The method of claim 1 or 2, wherein a restriction endonuclease used to create the GVT pair is EcoP 15 I, EcoP 1 I, Pst II, HinFIII, StyLT I, L1aF I, BceS I, Hine I, PhaB I, Hpy790545P, Hpy790639 I, or HpyAXIP.

15. The method of claim 14, wherein the restriction endonuclease is EcoP15 I.

16. The method of claim 14, wherein the restriction endonuclease is Pst II.

17. The method of claim 1 or 2, wherein a type IIS or type IIG restriction endonuclease is used to create the GVT pair and recognizes a six or more base pair uninterrupted recognition sequence.

18. The method of claim 1 or 2, wherein a type III restriction endonuclease is used to create the GVT pair and recognizes a six or more base pair uninterrupted recognition sequence.

30. The method of claim 1, further comprising isolating the created GVT-pair by restriction endonuclease digestion at sites that are on each DNA adaptor and are flanking the created GVT-pair.

32. The method according to claim 1, further comprising determining whether the target nucleic acid molecule has inversion by

generating at least two GVT-pairs of the target nucleic acid molecule;

determining orientation of each GVT pair; and

comparing the orientation of each GVT-pair;

wherein inconsistent orientation between the GVT-pairs indicates that the target nucleic acid molecule has inversion.

2. A method for producing juxtaposed genomic variation tags (GVTs) for determining fine-structural-variations wherein the juxtaposed GVTs comprise two constituent members of a tag pair (GVT-pair) of a target nucleic acid molecule, the method comprising:

a) providing a target nucleic acid molecule;

b) fragmenting the target nucleic acid molecule to form one or more fragmented target DNA inserts;

c) providing a linear plasmid vector, comprising at least a pair of restriction endonuclease recognition sequences, wherein each restriction endonuclease recognition sequence is located at a predetermined sequence position on each end of the plasmid vector;

d) ligating each end of the fragmented target DNA insert to each end of the plasmid vector, thereby forming a circular plasmid that carries the fragmented DNA insert, wherein the fragmented target DNA insert is flanked by the pair of restriction endonuclease recognition sequences, and each endonuclease recognition sequence directs cleavage of the fragmented target DNA insert at a distance from each end of the fragmented target insert;

e) digesting the circular plasmid that carries the fragmented DNA insert using restriction endonuclease molecules that recognize the restriction endonuclease recognition sequences on the plasmid vector, thereby cleaving the target DNA insert and creating a linear molecule comprising two sequence tags (GVTs), wherein each GVT comprises a terminal sequence of the target DNA insert, and each GVT is attached to one end of the plasmid vector;

f) recovering said linear molecule comprising two GVTs;

g) recircularizing said linear molecule by intra-molecular ligation, thereby creating a GVT-pair comprising two juxtaposed GVTs

h) corresponding the GVT pair to a reference nucleic acid molecule, wherein each GVT corresponds to a segment of the reference nucleic acid molecule;

i) determining separation distance and orientation between the GVT pair on the target nucleic acid molecule;

j) determining separation distance and orientation between the segments on the reference nucleic acid molecule; and

k) determining whether the target nucleic acid molecule has a fine-structural-variation as compared to the reference nucleic acid molecule by comparing the separation distance and orientation between the GVT pair with the separation distance between the segments on the reference nucleic acid molecule.

19. The method of claim 2, wherein the target DNA insert is genomic DNA, cDNA, viral DNA, microbial DNA, plastid DNA, chemically synthesized DNA, DNA product of nucleic acid amplification, or DNA transcribed from RNA.

31. The method of claim 2, further comprising isolating the created GVT-pair by restriction endonuclease digestion at sites that are on the plasmid vector and are flanking the created GVT-pair.

33. The method according to claim 2, further comprising determining whether the target nucleic acid molecule has inversion by

generating at least two GVT-pairs of the target nucleic acid molecule;

determining orientation of each GVT pair; and

comparing the orientation of each GVT-pair;

wherein inconsistent orientation between the GVT-pairs indicates that the target nucleic acid molecule has inversion.

3. A method to create a DNA oligomer through controlled and ordered ligation of short DNA monomers possessing palindromic, rotationally equivalent cohesive ends to yield an oligomeric product bound at both ends by an initiation adaptor, comprising the steps of:

forming an oligomer of DNA monomers initiated from an initiation adaptor wherein one adaptor terminus has a nonpalindromic cohesive end that cannot self-ligate, but can adhere to a vector, while the other adaptor terminus has a cohesive unphosphorylated end to prevent adaptor dimer formation and is complementary to the cohesive ends of the DNA monomer for ligation to monomer to initiate oligomer formation; and

terminating oligomer growth upon ligation of either a free initiation adaptor to the oligomer formed by adding the DNA monomers or by ligation of another oligomer initiated by the initiation adaptor;

wherein the oligomer so formed has an average length regulated by a molar ratio of DNA monomer to initiation adaptor measured when commencing formation of the oligomer.

20. A method for creating DNA sequence tag oligomers, comprising:

a) providing an amount of DNA sequence tag monomers, wherein each DNA sequence tag monomer comprises two cohesive ends, each cohesive end being complementary to a cohesive end of another DNA sequence tag monomer;

b) providing an amount of DNA initiation adaptors, each comprising a nonpalindromic cohesive end that cannot self-ligate and an unphosphorylated palindromic cohesive end that is complementary to a cohesive end of the DNA sequence tag monomers, wherein the DNA sequence tag monomers are provided in an excess molar amount as compared to the DNA initiation adaptors; and

c) contacting the excess molar amount of the DNA sequence tag monomers with the DNA initiation adaptors, thereby forming an initiation adaptor-ligated DNA sequence tag oligomer comprising a series of DNA sequence tag monomers ligated one to another, and wherein each end of the series of ligated DNA sequence tag monomers is attached to the nonpalindromic cohesive end of a DNA initiation adaptor.

21. The method according to claim 20, wherein each DNA sequence tag monomer comprises a GVT-pair.

22. The method according to claim 20, wherein a predetermined excess molar amount of the DNA sequence tag monomers are contacted with a predetermined molar amount of DNA initiation adaptors, thereby forming initiation adaptor-ligated DNA sequence tag oligomers that comprise, on average, a desired number of DNA sequence tag monomers, the desired number being related to the molar ratio of DNA initiation adaptors to DNA sequence tag monomers, wherein the molar ratio can be calculated as one part initiation adaptor to N parts monomer, where N equals (the desired number plus 2) divided by 2.

23. The method according to claim 21, further comprising:

d) providing a plasmid vector comprising a cohesive end that is complementary to the nonpalindromic cohesive end of the DNA initiation adaptors; and

e) ligating the plasmid vector to said oligomer, thereby forming a plasmid vector that carries the initiation adaptor-ligated DNA sequence tag oligomer.

24. A method for producing a multiplex sequencing vector that carries DNA sequence tags of interest, comprising:

a) providing a plurality of DNA sequence tags of interest,

b) providing a circular plasmid vector comprising a plurality of vector modules, wherein more than one of said vector modules comprise a type IIS endonuclease recognition sequence and a pair of DNA sequencing primer binding sites for priming Sanger dideoxy sequencing reactions, wherein the endonuclease recognition sequence directs cleavage of those more than one vector modules at a predetermined cleavage site on each module, and each side of said cleavage site is flanked by a DNA sequencing primer binding site;

c) digesting the circular plasmid vector using restriction endonuclease molecules that recognize the endonuclease recognition sequence on said more than one vector modules, thereby forming linear plasmid vectors;

d) ligating an end of a DNA sequence tag of interest to an end of each linear plasmid vector; and

e) reforming a circular plasmid vector from said linear plasmid vectors, thereby generating a circular multiplex sequencing vector that carries a plurality of the DNA sequence tags of interest.

25. The method according to claim 24, wherein each DNA sequence tag comprises a GVT-pair or a GVT-pair-oligomer.

26. The method according to claim 24, wherein the circular plasmid vector comprises a vector module comprising a drug selectable marker.

27. The method according to claim 24, wherein the circular plasmid vector comprises a vector module comprising a plasmid replicon for plasmid replication.

28. The method according to claim 24, wherein digestion of a vector module using restriction endonuclease molecules that recognize an endonuclease recognition sequence creates a nonpalindromic cohesive end.

29. The method according to claim 24, wherein the circular plasmid vector comprises a vector module that is free of recognition sites for Mme I, CstM I, NmeA III, EcoP15 I, Pst II, BamH I, Pst I, BspT I, or Kas I, and said vector module comprises Eco31 I and Esp3 I recognition sites.

34. The method of claim 26, wherein the drug selectable marker is free of Mme I, CstM I, NmeA III, EcoP15 I, Pst II, BamH I, Pst I, BspT I, or Kas I restriction endonuclease sites.

35. The method of claim 26, wherein the drug selectable marker codes for kanamycin resistance.

36. The method of claim 26, wherein the drug selectable marker codes for ampicillin resistance.

37. The method of claim 27, wherein the plasmid replicon is free of Mme I, CstM I, NmeA III, EcoP15 I, Pst II, BamH I, Pst I, BspT I, or Kas I restriction endonuclease sites.

38. The method of claim 27, wherein the plasmid replicon is P15A.

39. The method of claim 27, wherein the plasmid replicon is ColE1.

40. The method of claim 27, wherein the plasmid replicon is a ColE1 derivative of pUC.

41. The method of claim 24, wherein the circular plasmid vector comprises a vector module comprising a cloning site that is created by digestion of the vector module with a type II, type IIS, or a type IIG restriction endonuclease that recognizes a six or more base pair uninterrupted sequence.